AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma.

Published Date: 10 Apr 2024

A study presented at the annual conference suggests that patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma may benefit from cadonilimab plus chemotherapy in terms of both overall and progression-free survival.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot